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Official journal of the American College of Medical Genetics and Genomics Letter to the editor
De novo mutations in autosomal 
recessive congenital 
malformations
To the Editor: In suspected autosomal recessive disease without 
a genetic diagnosis, the risk to future pregnancies is generally 
reported as 25%, assuming inheritance of one causative allele 
from each parent. However, it is also possible that a de novo 
mutation (DNM) could contribute to disease in these cases. The 
contribution of DNMs to autosomal dominant developmental 
disorders is widely recognized, but their frequency in autoso-
mal recessive disease is thought to be low, as found in a recent 
Genetics in Medicine article by Retterer et al.,1 titled “Clinical 
Application of Whole-Exome Sequencing Across Clinical 
Indications,” and other studies.2,3
The genetic diagnosis of such conditions is important because 
it allows precise understanding of disease etiology and accu-
rate reporting of recurrence risk. This enables families to make 
informed decisions about future reproduction and provides the 
opportunity for earlier genetic screening in future pregnancies. 
Without a genetic diagnosis, recurrence risk is estimated on the 
basis of the clinical phenotype alone.
In a series of nine families in which severe fetal malformation 
led to the termination of a pregnancy, we used trio-based exome 
sequencing to identify two unrelated cases in which an autoso-
mal recessive disorder was caused by the combination of one de 
novo and one inherited variant. Compound heterozygous loss-of- 
function variants in EVC2 were identified in the first fetus. Variants 
in this gene have been shown to cause Ellis-van Creveld syndrome, 
which was consistent with the phenotype of the fetus. The first variant 
was a 1-bp deletion in exon 16 (ENST00000344408.5:c.2746delA) 
that results in a frameshift generating a premature stop codon 
(ENSP00000342144.5: p.Ser916AlafsTer6). This was inherited from 
the mother. The second was a de novo nonsense variant in exon 
18 (ENST00000344408.5:c.3141G>A; ENSP00000342144.5:p.
Trp1047Ter), which allele-specific polymerase chain reaction con-
firmed had arisen on the paternal haplotype.
In the second family, compound heterozygous loss-of-function 
variants in FRAS1 were identified in the fetus; these mutations 
cause Fraser syndrome, which was consistent with the pheno-
type. The first variant was a 20-bp deletion in exon 41 (ENST
00000264895.6:c.5664_5665+19delinsT), leading to the loss 
of two bases of coding sequence and a donor splice site, which 
is predicted to lead to skipping of exon 41 and a frameshift in 
the open reading frame, generating a premature stop codon 
(ENST00000264895.6:p.Asp1845ThrfsTer10). This variant was 
inherited from the mother. The second variant was a de novo 
1-bp deletion in exon 66 (ENST00000264895.6:c.10287delC), 
resulting in a frameshift mutation and a premature stop codon 
(ENSP00000264895.6:p.Tyr3429Ter). Allele-specific polymerase 
chain reaction confirmed that the DNM had arisen on the 
 paternal chromosome.
The variants were validated by Sanger sequencing, and the 
biological relationships within both trios were confirmed, 
showing that these were true DNMs. For these two fetuses, the 
clinical phenotypes were suggestive of autosomal recessive syn-
dromes with a reported recurrence risk of 25%. In both cases, 
because one of the causative variants arose de novo, the recur-
rence risk is markedly reduced, with significant implications 
for future reproductive decisions. A small finite risk remains, 
however, owing to the possibility of germ-line mosaicism in the 
father in both families.
Three recently published trio-based exome sequencing stud-
ies, each including several thousand cases, a proportion of 
which presented as congenital malformations, did not report 
a single case of recessive disorder in which one of the causative 
alleles was a DNM.1–3 Retterer et al.1 reported exome sequenc-
ing in more than 3,000 cases and Yang et  al.2 in more than 
2,000 cases; together these studies report more than 400 auto-
somal recessive molecular diagnoses, without a single case of 
a DNM contributing to the genetic etiology. The Deciphering 
Developmental Disorders project did not identify enrichment 
for any functional class of DNMs in autosomal recessive devel-
opmental disorder–linked genes.3 Although our study size is 
small, it suggests that DNMs may have a more important role 
in autosomal recessive congenital malformation than has previ-
ously been considered.
Given that the identification of a causative DNM in recessive 
disease leads to a low predicted recurrence risk but has hitherto 
been infrequently reported, we recommend that the frequency 
of this mode of inheritance be analyzed systematically in a 
larger series of cases, particularly in patients presenting with 
a congenital malformation. Future studies of recessive disease 
should specifically report whether this mechanism contributes 
to any of their cases. For accurate clinical reporting, this mode 
of inheritance should always be considered a possible contribu-
tor to the cause of autosomal recessive congenital malforma-
tion. Clinical confirmation of parental carrier status will help 
to ensure accurate reporting of recurrence risk in autosomal 
recessive disease.
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